Methods and Compositions Using Cetyl Myristoleate (CMO) In Medical Treatments
A therapeutic method of alleviating the symptoms of failed back surgery syndrome, post laminectomy syndrome, post-surgery syndrome, sympathetic dystrophies, macular degenerations, complex regional pain syndrome, reflex sympathetic dystrophy and neuropathies by administering to the afflicted subject a therapeutically effective amount of cetyl myristoleate alone, or in combination with selective effective amount of aspirin, gabapentin, pregabalin, duloxetine, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, neuroceuticals, Neurontin, Cymbalta, Lyrica, muscle relaxers, anti-depressants, nortriptyline, local anesthetics, and steroids..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Europäisches Patentamt - (2019) vom: 10. Jan. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEVIN BRUCE H [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2019-01-10, Last update posted on www.tib.eu: 2022-06-22, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
US2019008819 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA009930132 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA009930132 | ||
| 003 | DE-627 | ||
| 005 | 20230504124807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA009930132 | ||
| 035 | |a (EPA)US2019008819 | ||
| 035 | |a (EPA)64903683 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEVIN BRUCE H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methods and Compositions Using Cetyl Myristoleate (CMO) In Medical Treatments |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2019-01-10, Last update posted on www.tib.eu: 2022-06-22, Last updated: 2023-02-09 | ||
| 520 | |a A therapeutic method of alleviating the symptoms of failed back surgery syndrome, post laminectomy syndrome, post-surgery syndrome, sympathetic dystrophies, macular degenerations, complex regional pain syndrome, reflex sympathetic dystrophy and neuropathies by administering to the afflicted subject a therapeutically effective amount of cetyl myristoleate alone, or in combination with selective effective amount of aspirin, gabapentin, pregabalin, duloxetine, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, neuroceuticals, Neurontin, Cymbalta, Lyrica, muscle relaxers, anti-depressants, nortriptyline, local anesthetics, and steroids. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2019) vom: 10. Jan. |
| 773 | 1 | 8 | |g year:2019 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/64903683/publication/US2019008819A1?q=US2019008819 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2019 |b 10 |c 01 |
| 951 | |a AR | ||
| 952 | |j 2019 |b 10 |c 01 | ||